US경제·CNBC Business RSS· 번역 중
AI가 열심히 번역 중이에요 🤖
곧 한글 번역본을 제공해드릴게요. 잠시만 기다려주세요!
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
2026.08.05 23:35
AI 감성 분석
롱 (매수 신호)롱 62%숏 38%
Zepbound와 Mounjaro의 판매 급증이 예상 매출 가이던스 상향의 근거가 되어 주가에 강력한 추가 모멘텀을 제공할 것입니다.
핵심 요약
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Original Article
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Source: https://www.cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026.html